Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Free Report

White Paper_2017_State of China Life Science

State of China Life Science - 2017H1

Over $10B invested in last 18 months! Download free report on life science investment in China.

China Implements 30-Day Review for “Simple” M&A Transactions

publication date: Feb 26, 2014
View a Printer Friendly version of this page, allowing you to print the page.
China has introduced new M&A review procedures that will shorten approval times for most transactions to 30 days. The Ministry of Commerce estimates that up to 60% of all M&A events will qualify for this new fast-track decision. The major determinant for fast-track approval is market share: the proposed tie-up cannot creat a company with a commanding position in its market. If the resulting market share is large, MOFCOM will require as long as 180 days to render an opinion. More details....

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China